Home › Compare › NXLLF vs ABBV
NXLLF yields 200.00% · ABBV yields 3.06%● Live data
📍 NXLLF pulled ahead of the other in Year 1
Combined, NXLLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXLLF + ABBV for your $10,000?
Nuix Limited provides investigative analytics and intelligence software solutions in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The company offers Nuix Workstation, a solution for processing file formats and source types into meaningful information by capturing the content, metadata, and context; Nuix Discover that provides processing, analytics, and machine learning-powered review in a single platform; and Nuix Investigate, a solution which extracts, correlates, and contextualizes various types of data types, across people, objects, locations, and events. The company also provides Nuix Adaptive Security, monitors, detects, and responds to the threats of enterprises; Nuix Enterprise Collection Center, a solution to collect disk images or selected data from laptops, desktops, servers, enterprise file shares, and Microsoft sharepoint sites to legal, investigation, security, and compliance teams for investigation; Nuix Automation, a web-based multi-user graphical tool that allows to map out complex data processes across various activities and machines; and Nuix NLP, a solution which combines machine learning technologies with a proprietary language model to discover, understand, classify, and quantify text content. It serves corporations, governments, law enforcement industries, law firms, advisories, and service partners. The company was formerly known as Nuix Pty Ltd and changed its name to Nuix Limited in September 2020. Nuix Limited was founded in 2000 and is headquartered in Sydney, Australia.
Full NXLLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.